SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63320 355 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
63135So the common denominator here is not Elevidys, but the vector itself, which makghettogoulash1June 12
63134SRPT: A couple of corrections. Elevidys already has Full Approval in ambulatory ghettogoulash1June 12
63133Perhaps I was a little too glib in my first statement regarding SRPT risks. JusOlecranon1June 11
63132I’m going push back on that a little; the worst is just beginning.dorightbythem1June 11
63131That is certainly the hope. I have been increasing holdings in this range for aluckydog88-June 10
63130IMHO RFKJr’s worst is already priced in.Olecranon1June 10
63129well i guess the risk is RFK and the uncertainty he brings. this is what happenluckydog881June 9
63128IMHO, it’s rare to see a stock a stock like Sarepta with so much near/medium terOlecranon-June 9
63127came across this today: 03:01 PM EDT, 06/09/2025 (MT Newswires) -- Sarepta Therluckydog882June 9
63126Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perforluckydog882June 6
63125re: SRPT undervalued Right, but every damn time there's a buying opportuniterickerickson1June 5
63124I heard that new guy at FDA that spooked everyone (Prasad) about SRPT was intervstockdoc779May 28
63123Trodelvy® Demonstrates Highly Statistically Significant & Clinically MeOlecranon10May 23
63122Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatluckydog883May 21
63121Thanks again for all that, allatwwk. I’m surprised that UNH medicare fraud was Olecranon-May 19
63120I enjoyed the conference a lot. Panel after panel, really good questions from aallatwwk1May 17
63119Thanks, allatwwk. Were you happy with the quality of the information presented?Olecranon-May 17
63118Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAluckydog882May 16
63117Companies ranked high on innovation and invention at the STAT conference. The prallatwwk2May 15
63116Approval by Japan is a huge vote of confidence in elevydis. The Japanese are nostockdoc7710May 14
63115ctmx acquired price abbv imgn approved product 1 indicationforgetme-May 13
63114for those following srpt: Sarepta Therapeutics Announces Approval in Japan of ELluckydog883May 13
63113ctmx abbv met adc data medium 3rd line pts were not as sick Efficacy: ORR: 18% forgetme1May 12
63112ctmx great data and wider application than immu trop adcforgetme-May 12
63111Not to mention polluting the oceansEMU2-May 10
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News